Biogroup - comment

The new format of HY conference calls, which gives preference to typed questions rather than live telephone inquiries, has resulted in repetitive queries and limited follow-up, reducing the depth of discussion prompted by management’s responses. This pattern was evident again during BioGroup’s Q2 call yesterday, which offered little new insight. Management confirmed that minority put options now total €275m. However, they declined to comment on the potential impact of recent recommendations from various French agencies on pricing dynamics within the health testing subsector.